 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Viral protein
|
PDB id
|
|
|
|
1exq
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.2.7.7.49
- RNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1)
|
 |
 |
 |
 |
 |
Deoxynucleoside triphosphate
|
+
|
DNA(n)
|
=
|
diphosphate
|
+
|
DNA(n+1)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.2.7.7.7
- DNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1)
|
 |
 |
 |
 |
 |
Deoxynucleoside triphosphate
|
+
|
DNA(n)
|
=
|
diphosphate
|
+
|
DNA(n+1)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
E.C.3.1.13.2
- Exoribonuclease H.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
|
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
E.C.3.1.26.13
- Retroviral ribonuclease H.
|
|
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
E.C.3.4.23.16
- HIV-1 retropepsin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro.
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biological process
|
DNA integration
|
1 term
|
 |
|
Biochemical function
|
nucleic acid binding
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
97:8233-8238
(2000)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding.
|
|
J.C.Chen,
J.Krucinski,
L.J.Miercke,
J.S.Finer-Moore,
A.H.Tang,
A.D.Leavitt,
R.M.Stroud.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Insolubility of full-length HIV-1 integrase (IN) limited previous structure
analyses to individual domains. By introducing five point mutations, we
engineered a more soluble IN that allowed us to generate multidomain HIV-1 IN
crystals. The first multidomain HIV-1 IN structure is reported. It incorporates
the catalytic core and C-terminal domains (residues 52-288). The structure
resolved to 2.8 A is a Y-shaped dimer. Within the dimer, the catalytic core
domains form the only dimer interface, and the C-terminal domains are located 55
A apart. A 26-aa alpha-helix, alpha6, links the C-terminal domain to the
catalytic core. A kink in one of the two alpha6 helices occurs near a known
proteolytic site, suggesting that it may act as a flexible elbow to reorient the
domains during the integration process. Two proteins that bind DNA in a
sequence-independent manner are structurally homologous to the HIV-1 IN
C-terminal domain, suggesting a similar protein-DNA interaction in which the IN
C-terminal domain may serve to bind, bend, and orient viral DNA during
integration. A strip of positively charged amino acids contributed by both
monomers emerges from each active site of the dimer, suggesting a minimally
dimeric platform for binding each viral DNA end. The crystal structure of the
isolated catalytic core domain (residues 52-210), independently determined at
1.6-A resolution, is identical to the core domain within the two-domain 52-288
structure.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. HIV-1 IN activities. A schematic diagram of HIV-1
IN activities depicts the double-stranded DNA viral genome at
the top as parallel black lines with the terminal nucleotides
CAGT. The conserved 3' CA dinucleotide is underlined at each
viral end. IN first acts in the cytoplasm to remove the two 3'
nucleotides (3' processing), leaving a 2-nt overhang at each 5'
end. In the nucleus, IN mediates a concerted integration (strand
transfer) by ligating each 3' end of the viral DNA (looped
structure) to the host DNA (striped lines). This generates a
"gapped intermediate" with free viral 5' ends that are repaired
to generate the fully integrated provirus. The characteristic
HIV-1 5-bp staggered strand transfer is depicted by the letters
A-E in the target DNA, and the resulting 5-bp direct repeats
(DR) of host DNA flanking the provirus are indicated.
|
 |
Figure 2.
Fig. 2. Structure of HIV-1 IN52-288. (a) Stereoview of
the HIV-1 IN52-288 dimer, composed of monomer A (blue) and
monomer B (green). Monomer B catalytic residues D64, D116, and
E152 are indicated (brown dots), and the N and C termini of each
monomer are labeled. Immunologically critical residue W235 is
located on the surface. Mutated residues C56S, W131D, F139D, and
F185K are indicated, except for C280S, which is disordered. (b)
The HIV-1 IN52-288 dimer rotated by 90° with respect to a.
Catalytic residues are highlighted in brown. (c) Alignment of
residues 195-210 in 6
demonstrates the kink at T210 that creates a 90°
rotation of the C-terminal domains relative to one another as
illustrated by the position of P233. Figure was generated by
MOLSCRIPT (44) and RASTER3D (45).
|
 |
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.Wielens,
S.J.Headey,
J.J.Deadman,
D.I.Rhodes,
M.W.Parker,
D.K.Chalmers,
and
M.J.Scanlon
(2011).
Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1.
|
| |
ChemMedChem, 6,
258-261.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Q.Al-Mawsawi,
and
N.Neamati
(2011).
Allosteric Inhibitor Development Targeting HIV-1 Integrase.
|
| |
ChemMedChem, 6,
228-241.
|
 |
|
|
|
|
 |
M.Huang,
G.H.Grant,
and
W.G.Richards
(2011).
Binding modes of diketo-acid inhibitors of HIV-1 integrase: A comparative molecular dynamics simulation study.
|
| |
J Mol Graph Model, 29,
956-964.
|
 |
|
|
|
|
 |
N.C.Fitzkee,
D.A.Torchia,
and
A.Bax
(2011).
Measuring rapid hydrogen exchange in the homodimeric 36 kDa HIV-1 integrase catalytic core domain.
|
| |
Protein Sci, 20,
500-512.
|
 |
|
|
|
|
 |
C.Tintori,
N.Veljkovic,
V.Veljkovic,
and
M.Botta
(2010).
Computational studies of the interaction between the HIV-1 integrase tetramer and the cofactor LEDGF/p75: insights from molecular dynamics simulations and the Informational spectrum method.
|
| |
Proteins, 78,
3396-3408.
|
 |
|
|
|
|
 |
F.Ceccherini-Silberstein,
I.Malet,
L.Fabeni,
S.Dimonte,
V.Svicher,
R.D'Arrigo,
A.Artese,
G.Costa,
S.Bono,
S.Alcaro,
A.Monforte,
C.Katlama,
V.Calvez,
A.Antinori,
A.G.Marcelin,
and
C.F.Perno
(2010).
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
|
| |
J Antimicrob Chemother, 65,
2305-2318.
|
 |
|
|
|
|
 |
J.J.Tan,
X.J.Cong,
L.M.Hu,
C.X.Wang,
L.Jia,
and
X.J.Liang
(2010).
Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.
|
| |
Drug Discov Today, 15,
186-197.
|
 |
|
|
|
|
 |
J.M.Doolittle,
and
S.M.Gomez
(2010).
Structural similarity-based predictions of protein interactions between HIV-1 and Homo sapiens.
|
| |
Virol J, 7,
82.
|
 |
|
|
|
|
 |
K.Carayon,
H.Leh,
E.Henry,
F.Simon,
J.F.Mouscadet,
and
E.Deprez
(2010).
A cooperative and specific DNA-binding mode of HIV-1 integrase depends on the nature of the metallic cofactor and involves the zinc-containing N-terminal domain.
|
| |
Nucleic Acids Res, 38,
3692-3708.
|
 |
|
|
|
|
 |
K.Gupta,
T.Diamond,
Y.Hwang,
F.Bushman,
and
G.D.Van Duyne
(2010).
Structural properties of HIV integrase. Lens epithelium-derived growth factor oligomers.
|
| |
J Biol Chem, 285,
20303-20315.
|
 |
|
|
|
|
 |
L.Krishnan,
X.Li,
H.L.Naraharisetty,
S.Hare,
P.Cherepanov,
and
A.Engelman
(2010).
Structure-based modeling of the functional HIV-1 intasome and its inhibition.
|
| |
Proc Natl Acad Sci U S A, 107,
15910-15915.
|
 |
|
|
|
|
 |
M.Métifiot,
C.Marchand,
K.Maddali,
and
Y.Pommier
(2010).
Resistance to Integrase Inhibitors.
|
| |
Viruses, 2,
1347-1366.
|
 |
|
|
|
|
 |
M.S.Briones,
and
S.A.Chow
(2010).
A new functional role of HIV-1 integrase during uncoating of the viral core.
|
| |
Immunol Res, 48,
14-26.
|
 |
|
|
|
|
 |
N.C.Fitzkee,
and
A.Bax
(2010).
Facile measurement of ¹H-¹⁵N residual dipolar couplings in larger perdeuterated proteins.
|
| |
J Biomol NMR, 48,
65-70.
|
 |
|
|
|
|
 |
S.Azzi,
V.Parissi,
R.G.Maroun,
P.Eid,
O.Mauffret,
and
S.Fermandjian
(2010).
The HIV-1 integrase α4-helix involved in LTR-DNA recognition is also a highly antigenic peptide element.
|
| |
PLoS One, 5,
e16001.
|
 |
|
|
|
|
 |
S.Hare,
S.S.Gupta,
E.Valkov,
A.Engelman,
and
P.Cherepanov
(2010).
Retroviral intasome assembly and inhibition of DNA strand transfer.
|
| |
Nature, 464,
232-236.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
V.Varghese,
T.F.Liu,
S.Y.Rhee,
P.Libiran,
C.Trevino,
W.J.Fessel,
and
R.W.Shafer
(2010).
HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
|
| |
AIDS Res Hum Retroviruses, 26,
1323-1326.
|
 |
|
|
|
|
 |
Y.Zheng,
Z.Ao,
K.D.Jayappa,
and
X.Yao
(2010).
Characterization of the HIV-1 integrase chromatin- and LEDGF/p75-binding abilities by mutagenic analysis within the catalytic core domain of integrase.
|
| |
Virol J, 7,
68.
|
 |
|
|
|
|
 |
A.Alian,
S.L.Griner,
V.Chiang,
M.Tsiang,
G.Jones,
G.Birkus,
R.Geleziunas,
A.D.Leavitt,
and
R.M.Stroud
(2009).
Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs.
|
| |
Proc Natl Acad Sci U S A, 106,
8192-8197.
|
 |
|
|
|
|
 |
A.Levin,
Z.Hayouka,
M.Helfer,
R.Brack-Werner,
A.Friedler,
and
A.Loyter
(2009).
Peptides derived from HIV-1 integrase that bind Rev stimulate viral genome integration.
|
| |
PLoS ONE, 4,
e4155.
|
 |
|
|
|
|
 |
C.J.McKee,
J.J.Kessl,
J.O.Norris,
N.Shkriabai,
and
M.Kvaratskhelia
(2009).
Mass spectrometry-based footprinting of protein-protein interactions.
|
| |
Methods, 47,
304-307.
|
 |
|
|
|
|
 |
C.Marchand,
K.Maddali,
M.Métifiot,
and
Y.Pommier
(2009).
HIV-1 IN inhibitors: 2010 update and perspectives.
|
| |
Curr Top Med Chem, 9,
1016-1037.
|
 |
|
|
|
|
 |
E.Valkov,
S.S.Gupta,
S.Hare,
A.Helander,
P.Roversi,
M.McClure,
and
P.Cherepanov
(2009).
Functional and structural characterization of the integrase from the prototype foamy virus.
|
| |
Nucleic Acids Res, 37,
243-255.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
F.Michel,
C.Crucifix,
F.Granger,
S.Eiler,
J.F.Mouscadet,
S.Korolev,
J.Agapkina,
R.Ziganshin,
M.Gottikh,
A.Nazabal,
S.Emiliani,
R.Benarous,
D.Moras,
P.Schultz,
and
M.Ruff
(2009).
Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor.
|
| |
EMBO J, 28,
980-991.
|
 |
|
|
|
|
 |
H.Merad,
H.Porumb,
L.Zargarian,
B.René,
Z.Hobaika,
R.G.Maroun,
O.Mauffret,
and
S.Fermandjian
(2009).
An unusual helix turn helix motif in the catalytic core of HIV-1 integrase binds viral DNA and LEDGF.
|
| |
PLoS ONE, 4,
e4081.
|
 |
|
|
|
|
 |
J.J.Kessl,
J.O.Eidahl,
N.Shkriabai,
Z.Zhao,
C.J.McKee,
S.Hess,
T.R.Burke,
and
M.Kvaratskhelia
(2009).
An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule.
|
| |
Mol Pharmacol, 76,
824-832.
|
 |
|
|
|
|
 |
M.J.Dar,
B.Monel,
L.Krishnan,
M.C.Shun,
F.Di Nunzio,
D.E.Helland,
and
A.Engelman
(2009).
Biochemical and virological analysis of the 18-residue C-terminal tail of HIV-1 integrase.
|
| |
Retrovirology, 6,
94.
|
 |
|
|
|
|
 |
M.Jaskolski,
J.N.Alexandratos,
G.Bujacz,
and
A.Wlodawer
(2009).
Piecing together the structure of retroviral integrase, an important target in AIDS therapy.
|
| |
FEBS J, 276,
2926-2946.
|
 |
|
|
|
|
 |
M.L.Barreca,
N.Iraci,
L.De Luca,
and
A.Chimirri
(2009).
Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.
|
| |
ChemMedChem, 4,
1446-1456.
|
 |
|
|
|
|
 |
S.Hare,
F.Di Nunzio,
A.Labeja,
J.Wang,
A.Engelman,
and
P.Cherepanov
(2009).
Structural basis for functional tetramerization of lentiviral integrase.
|
| |
PLoS Pathog, 5,
e1000515.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.A.Wilkinson,
K.Januszyk,
M.L.Phillips,
S.S.Tekeste,
M.Zhang,
J.T.Miller,
S.F.Le Grice,
R.T.Clubb,
and
S.A.Chow
(2009).
Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase.
|
| |
J Biol Chem, 284,
7931-7939.
|
 |
|
|
|
|
 |
A.Hombrouck,
A.Voet,
B.Van Remoortel,
C.Desadeleer,
M.De Maeyer,
Z.Debyser,
and
M.Witvrouw
(2008).
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
|
| |
Antimicrob Agents Chemother, 52,
2069-2078.
|
 |
|
|
|
|
 |
C.J.McKee,
J.J.Kessl,
N.Shkriabai,
M.J.Dar,
A.Engelman,
and
M.Kvaratskhelia
(2008).
Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein.
|
| |
J Biol Chem, 283,
31802-31812.
|
 |
|
|
|
|
 |
K.K.Pandey,
and
D.P.Grandgenett
(2008).
HIV-1 Integrase Strand Transfer Inhibitors: Novel Insights into their Mechanism of Action.
|
| |
Retrovirology, 2,
11-16.
|
 |
|
|
|
|
 |
L.Du,
L.Shen,
Z.Yu,
J.Chen,
Y.Guo,
Y.Tang,
X.Shen,
and
H.Jiang
(2008).
Hyrtiosal, from the marine sponge Hyrtios erectus, inhibits HIV-1 integrase binding to viral DNA by a new inhibitor binding site.
|
| |
ChemMedChem, 3,
173-180.
|
 |
|
|
|
|
 |
O.Delelis,
K.Carayon,
A.Saïb,
E.Deprez,
and
J.F.Mouscadet
(2008).
Integrase and integration: biochemical activities of HIV-1 integrase.
|
| |
Retrovirology, 5,
114.
|
 |
|
|
|
|
 |
R.W.Shafer,
and
J.M.Schapiro
(2008).
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.
|
| |
AIDS Rev, 10,
67-84.
|
 |
|
|
|
|
 |
S.Y.Rhee,
T.F.Liu,
M.Kiuchi,
R.Zioni,
R.J.Gifford,
S.P.Holmes,
and
R.W.Shafer
(2008).
Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.
|
| |
Retrovirology, 5,
74.
|
 |
|
|
|
|
 |
Z.Zhao,
C.J.McKee,
J.J.Kessl,
W.L.Santos,
J.E.Daigle,
A.Engelman,
G.Verdine,
and
M.Kvaratskhelia
(2008).
Subunit-specific protein footprinting reveals significant structural rearrangements and a role for N-terminal Lys-14 of HIV-1 Integrase during viral DNA binding.
|
| |
J Biol Chem, 283,
5632-5641.
|
 |
|
|
|
|
 |
E.De Clercq
(2007).
The design of drugs for HIV and HCV.
|
| |
Nat Rev Drug Discov, 6,
1001-1018.
|
 |
|
|
|
|
 |
G.Ren,
K.Gao,
F.D.Bushman,
and
M.Yeager
(2007).
Single-particle image reconstruction of a tetramer of HIV integrase bound to DNA.
|
| |
J Mol Biol, 366,
286-294.
|
 |
|
|
|
|
 |
H.Q.He,
X.H.Ma,
B.Liu,
X.Y.Zhang,
W.Z.Chen,
C.X.Wang,
and
S.H.Cheng
(2007).
High-throughput real-time assay based on molecular beacons for HIV-1 integrase 3'-processing reaction.
|
| |
Acta Pharmacol Sin, 28,
811-817.
|
 |
|
|
|
|
 |
L.Berthoux,
S.Sebastian,
M.A.Muesing,
and
J.Luban
(2007).
The role of lysine 186 in HIV-1 integrase multimerization.
|
| |
Virology, 364,
227-236.
|
 |
|
|
|
|
 |
M.Topper,
Y.Luo,
M.Zhadina,
K.Mohammed,
L.Smith,
and
M.A.Muesing
(2007).
Posttranslational acetylation of the human immunodeficiency virus type 1 integrase carboxyl-terminal domain is dispensable for viral replication.
|
| |
J Virol, 81,
3012-3017.
|
 |
|
|
|
|
 |
S.Baranova,
F.V.Tuzikov,
O.D.Zakharova,
N.A.Tuzikova,
C.Calmels,
S.Litvak,
L.Tarrago-Litvak,
V.Parissi,
and
G.A.Nevinsky
(2007).
Small-angle X-ray characterization of the nucleoprotein complexes resulting from DNA-induced oligomerization of HIV-1 integrase.
|
| |
Nucleic Acids Res, 35,
975-987.
|
 |
|
|
|
|
 |
A.Chen,
I.T.Weber,
R.W.Harrison,
and
J.Leis
(2006).
Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends.
|
| |
J Biol Chem, 281,
4173-4182.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Savarino
(2006).
A historical sketch of the discovery and development of HIV-1 integrase inhibitors.
|
| |
Expert Opin Investig Drugs, 15,
1507-1522.
|
 |
|
|
|
|
 |
C.H.Lu,
Y.S.Lin,
Y.C.Chen,
C.S.Yu,
S.Y.Chang,
and
J.K.Hwang
(2006).
The fragment transformation method to detect the protein structural motifs.
|
| |
Proteins, 63,
636-643.
|
 |
|
|
|
|
 |
C.Marchand,
A.A.Johnson,
E.Semenova,
and
Y.Pommier
(2006).
Mechanisms and inhibition of HIV integration.
|
| |
Drug Discov Today Dis Mech, 3,
253-260.
|
 |
|
|
|
|
 |
J.M.Richardson,
A.Dawson,
N.O'Hagan,
P.Taylor,
D.J.Finnegan,
and
M.D.Walkinshaw
(2006).
Mechanism of Mos1 transposition: insights from structural analysis.
|
| |
EMBO J, 25,
1324-1334.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Puglia,
T.Wang,
C.Smith-Snyder,
M.Cote,
M.Scher,
J.N.Pelletier,
S.John,
C.B.Jonsson,
and
M.J.Roth
(2006).
Revealing domain structure through linker-scanning analysis of the murine leukemia virus (MuLV) RNase H and MuLV and human immunodeficiency virus type 1 integrase proteins.
|
| |
J Virol, 80,
9497-9510.
|
 |
|
|
|
|
 |
J.Ramcharan,
D.M.Colleluori,
G.Merkel,
M.D.Andrake,
and
A.M.Skalka
(2006).
Mode of inhibition of HIV-1 Integrase by a C-terminal domain-specific monoclonal antibody.
|
| |
Retrovirology, 3,
34.
|
 |
|
|
|
|
 |
L.Q.Al-Mawsawi,
V.Fikkert,
R.Dayam,
M.Witvrouw,
T.R.Burke,
C.H.Borchers,
and
N.Neamati
(2006).
Discovery of a small-molecule HIV-1 integrase inhibitor-binding site.
|
| |
Proc Natl Acad Sci U S A, 103,
10080-10085.
|
 |
|
|
|
|
 |
S.Kehlenbeck,
U.Betz,
A.Birkmann,
B.Fast,
A.H.Göller,
K.Henninger,
T.Lowinger,
D.Marrero,
A.Paessens,
D.Paulsen,
V.Pevzner,
R.Schohe-Loop,
H.Tsujishita,
R.Welker,
J.Kreuter,
H.Rübsamen-Waigmann,
and
F.Dittmer
(2006).
Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.
|
| |
J Virol, 80,
6883-6894.
|
 |
|
|
|
|
 |
A.Brigo,
K.W.Lee,
G.Iurcu Mustata,
and
J.M.Briggs
(2005).
Comparison of multiple molecular dynamics trajectories calculated for the drug-resistant HIV-1 integrase T66I/M154I catalytic domain.
|
| |
Biophys J, 88,
3072-3082.
|
 |
|
|
|
|
 |
A.Loregian,
and
G.Palù
(2005).
Disruption of protein-protein interactions: towards new targets for chemotherapy.
|
| |
J Cell Physiol, 204,
750-762.
|
 |
|
|
|
|
 |
A.T.Phan,
V.Kuryavyi,
J.B.Ma,
A.Faure,
M.L.Andréola,
and
D.J.Patel
(2005).
An interlocked dimeric parallel-stranded DNA quadruplex: a potent inhibitor of HIV-1 integrase.
|
| |
Proc Natl Acad Sci U S A, 102,
634-639.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
B.Ason,
D.J.Knauss,
A.M.Balke,
G.Merkel,
A.M.Skalka,
and
W.S.Reznikoff
(2005).
Targeting Tn5 transposase identifies human immunodeficiency virus type 1 inhibitors.
|
| |
Antimicrob Agents Chemother, 49,
2035-2043.
|
 |
|
|
|
|
 |
J.Didierjean,
C.Isel,
F.Querré,
J.F.Mouscadet,
A.M.Aubertin,
J.Y.Valnot,
S.R.Piettre,
and
R.Marquet
(2005).
Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones.
|
| |
Antimicrob Agents Chemother, 49,
4884-4894.
|
 |
|
|
|
|
 |
J.G.Renisio,
S.Cosquer,
I.Cherrak,
S.El Antri,
O.Mauffret,
and
S.Fermandjian
(2005).
Pre-organized structure of viral DNA at the binding-processing site of HIV-1 integrase.
|
| |
Nucleic Acids Res, 33,
1970-1981.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Snásel,
Z.Krejcík,
V.Jencová,
I.Rosenberg,
T.Ruml,
J.Alexandratos,
A.Gustchina,
and
I.Pichová
(2005).
Integrase of Mason-Pfizer monkey virus.
|
| |
FEBS J, 272,
203-216.
|
 |
|
|
|
|
 |
J.Wielens,
I.T.Crosby,
and
D.K.Chalmers
(2005).
A three-dimensional model of the human immunodeficiency virus type 1 integration complex.
|
| |
J Comput Aided Mol Des, 19,
301-317.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.C.Lee,
J.Deng,
J.M.Briggs,
and
Y.Duan
(2005).
Large-scale conformational dynamics of the HIV-1 integrase core domain and its catalytic loop mutants.
|
| |
Biophys J, 88,
3133-3146.
|
 |
|
|
|
|
 |
R.Lu,
A.Limón,
H.Z.Ghory,
and
A.Engelman
(2005).
Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase.
|
| |
J Virol, 79,
2493-2505.
|
 |
|
|
|
|
 |
R.Lu,
H.Z.Ghory,
and
A.Engelman
(2005).
Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase.
|
| |
J Virol, 79,
10356-10368.
|
 |
|
|
|
|
 |
R.Lu,
N.Vandegraaff,
P.Cherepanov,
and
A.Engelman
(2005).
Lys-34, dispensable for integrase catalysis, is required for preintegration complex function and human immunodeficiency virus type 1 replication.
|
| |
J Virol, 79,
12584-12591.
|
 |
|
|
|
|
 |
T.L.Diamond,
and
F.D.Bushman
(2005).
Division of labor within human immunodeficiency virus integrase complexes: determinants of catalysis and target DNA capture.
|
| |
J Virol, 79,
15376-15387.
|
 |
|
|
|
|
 |
Y.Pommier,
A.A.Johnson,
and
C.Marchand
(2005).
Integrase inhibitors to treat HIV/AIDS.
|
| |
Nat Rev Drug Discov, 4,
236-248.
|
 |
|
|
|
|
 |
C.Calmels,
V.R.de Soultrait,
A.Caumont,
C.Desjobert,
A.Faure,
M.Fournier,
L.Tarrago-Litvak,
and
V.Parissi
(2004).
Biochemical and random mutagenesis analysis of the region carrying the catalytic E152 amino acid of HIV-1 integrase.
|
| |
Nucleic Acids Res, 32,
1527-1538.
|
 |
|
|
|
|
 |
D.J.Hazuda,
N.J.Anthony,
R.P.Gomez,
S.M.Jolly,
J.S.Wai,
L.Zhuang,
T.E.Fisher,
M.Embrey,
J.P.Guare,
M.S.Egbertson,
J.P.Vacca,
J.R.Huff,
P.J.Felock,
M.V.Witmer,
K.A.Stillmock,
R.Danovich,
J.Grobler,
M.D.Miller,
A.S.Espeseth,
L.Jin,
I.W.Chen,
J.H.Lin,
K.Kassahun,
J.D.Ellis,
B.K.Wong,
W.Xu,
P.G.Pearson,
W.A.Schleif,
R.Cortese,
E.Emini,
V.Summa,
M.K.Holloway,
and
S.D.Young
(2004).
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.
|
| |
Proc Natl Acad Sci U S A, 101,
11233-11238.
|
 |
|
|
|
|
 |
E.S.Svarovskaia,
R.Barr,
X.Zhang,
G.C.Pais,
C.Marchand,
Y.Pommier,
T.R.Burke,
and
V.K.Pathak
(2004).
Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.
|
| |
J Virol, 78,
3210-3222.
|
 |
|
|
|
|
 |
J.Agapkina,
M.Smolov,
E.Zubin,
J.F.Mouscadet,
and
M.Gottikh
(2004).
HIV-1 integrase can process a 3'-end crosslinked substrate.
|
| |
Eur J Biochem, 271,
205-211.
|
 |
|
|
|
|
 |
J.M.Richardson,
L.Zhang,
S.Marcos,
D.J.Finnegan,
M.M.Harding,
P.Taylor,
and
M.D.Walkinshaw
(2004).
Expression, purification and preliminary crystallographic studies of a single-point mutant of Mos1 mariner transposase.
|
| |
Acta Crystallogr D Biol Crystallogr, 60,
962-964.
|
 |
|
|
|
|
 |
K.Gao,
S.Wong,
and
F.Bushman
(2004).
Metal binding by the D,DX35E motif of human immunodeficiency virus type 1 integrase: selective rescue of Cys substitutions by Mn2+ in vitro.
|
| |
J Virol, 78,
6715-6722.
|
 |
|
|
|
|
 |
K.Zhu,
C.Dobard,
and
S.A.Chow
(2004).
Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase.
|
| |
J Virol, 78,
5045-5055.
|
 |
|
|
|
|
 |
N.Shkriabai,
S.S.Patil,
S.Hess,
S.R.Budihas,
R.Craigie,
T.R.Burke,
S.F.Le Grice,
and
M.Kvaratskhelia
(2004).
Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry.
|
| |
Proc Natl Acad Sci U S A, 101,
6894-6899.
|
 |
|
|
|
|
 |
R.G.Karki,
Y.Tang,
T.R.Burke,
and
M.C.Nicklaus
(2004).
Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design.
|
| |
J Comput Aided Mol Des, 18,
739-760.
|
 |
|
|
|
|
 |
T.Ikeda,
H.Nishitsuji,
X.Zhou,
N.Nara,
T.Ohashi,
M.Kannagi,
and
T.Masuda
(2004).
Evaluation of the functional involvement of human immunodeficiency virus type 1 integrase in nuclear import of viral cDNA during acute infection.
|
| |
J Virol, 78,
11563-11573.
|
 |
|
|
|
|
 |
V.Fikkert,
A.Hombrouck,
B.Van Remoortel,
M.De Maeyer,
C.Pannecouque,
E.De Clercq,
Z.Debyser,
and
M.Witvrouw
(2004).
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.
|
| |
AIDS, 18,
2019-2028.
|
 |
|
|
|
|
 |
A.A.Podtelezhnikov,
K.Gao,
F.D.Bushman,
and
J.A.McCammon
(2003).
Modeling HIV-1 integrase complexes based on their hydrodynamic properties.
|
| |
Biopolymers, 68,
110-120.
|
 |
|
|
|
|
 |
A.L.Gall,
M.Ruff,
and
D.Moras
(2003).
The dual role of CHAPS in the crystallization of stromelysin-3 catalytic domain.
|
| |
Acta Crystallogr D Biol Crystallogr, 59,
603-606.
|
 |
|
|
|
|
 |
J.Bischerour,
H.Leh,
E.Deprez,
J.C.Brochon,
and
J.F.Mouscadet
(2003).
Disulfide-linked integrase oligomers involving C280 residues are formed in vitro and in vivo but are not essential for human immunodeficiency virus replication.
|
| |
J Virol, 77,
135-141.
|
 |
|
|
|
|
 |
J.Polanski
(2003).
Self-organizing neural networks for pharmacophore mapping.
|
| |
Adv Drug Deliv Rev, 55,
1149-1162.
|
 |
|
|
|
|
 |
K.Moreau,
C.Faure,
S.Violot,
G.Verdier,
and
C.Ronfort
(2003).
Mutations in the C-terminal domain of ALSV (Avian Leukemia and Sarcoma Viruses) integrase alter the concerted DNA integration process in vitro.
|
| |
Eur J Biochem, 270,
4426-4438.
|
 |
|
|
|
|
 |
R.Chiu,
and
D.P.Grandgenett
(2003).
Molecular and genetic determinants of rous sarcoma virus integrase for concerted DNA integration.
|
| |
J Virol, 77,
6482-6492.
|
 |
|
|
|
|
 |
V.Fikkert,
B.Van Maele,
J.Vercammen,
A.Hantson,
B.Van Remoortel,
M.Michiels,
C.Gurnari,
C.Pannecouque,
M.De Maeyer,
Y.Engelborghs,
E.De Clercq,
Z.Debyser,
and
M.Witvrouw
(2003).
Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.
|
| |
J Virol, 77,
11459-11470.
|
 |
|
|
|
|
 |
A.Loregian,
H.S.Marsden,
and
G.Palù
(2002).
Protein-protein interactions as targets for antiviral chemotherapy.
|
| |
Rev Med Virol, 12,
239-262.
|
 |
|
|
|
|
 |
A.Wlodawer
(2002).
Rational approach to AIDS drug design through structural biology.
|
| |
Annu Rev Med, 53,
595-614.
|
 |
|
|
|
|
 |
A.Wlodawer
(2002).
Structure-based design of AIDS drugs and the development of resistance.
|
| |
Vox Sang, 83,
23-26.
|
 |
|
|
|
|
 |
N.Sluis-Cremer,
and
G.Tachedjian
(2002).
Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules.
|
| |
Eur J Biochem, 269,
5103-5111.
|
 |
|
|
|
|
 |
A.L.Harper,
L.M.Skinner,
M.Sudol,
and
M.Katzman
(2001).
Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection.
|
| |
J Virol, 75,
7756-7762.
|
 |
|
|
|
|
 |
C.Laboulais,
E.Deprez,
H.Leh,
J.F.Mouscadet,
J.C.Brochon,
and
M.Le Bret
(2001).
HIV-1 integrase catalytic core: molecular dynamics and simulated fluorescence decays.
|
| |
Biophys J, 81,
473-489.
|
 |
|
|
|
|
 |
E.Deprez,
P.Tauc,
H.Leh,
J.F.Mouscadet,
C.Auclair,
M.E.Hawkins,
and
J.C.Brochon
(2001).
DNA binding induces dissociation of the multimeric form of HIV-1 integrase: a time-resolved fluorescence anisotropy study.
|
| |
Proc Natl Acad Sci U S A, 98,
10090-10095.
|
 |
|
|
|
|
 |
F.Bertola,
C.Manigand,
P.Picard,
M.Goetz,
J.M.Schmitter,
and
G.Precigoux
(2001).
N-Terminal domain of HTLV-I integrase. Complexation and conformational studies of the zinc finger.
|
| |
J Pept Sci, 7,
588-597.
|
 |
|
|
|
|
 |
F.Yang,
and
M.J.Roth
(2001).
Assembly and catalysis of concerted two-end integration events by Moloney murine leukemia virus integrase.
|
| |
J Virol, 75,
9561-9570.
|
 |
|
|
|
|
 |
J.Y.Fang,
J.A.Mikovits,
R.Bagni,
C.L.Petrow-Sadowski,
and
F.W.Ruscetti
(2001).
Infection of lymphoid cells by integration-defective human immunodeficiency virus type 1 increases de novo methylation.
|
| |
J Virol, 75,
9753-9761.
|
 |
|
|
|
|
 |
J.Y.Wang,
H.Ling,
W.Yang,
and
R.Craigie
(2001).
Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein.
|
| |
EMBO J, 20,
7333-7343.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Gao,
S.L.Butler,
and
F.Bushman
(2001).
Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes.
|
| |
EMBO J, 20,
3565-3576.
|
 |
|
|
|
|
 |
M.Bouyac-Bertoia,
J.D.Dvorin,
R.A.Fouchier,
Y.Jenkins,
B.E.Meyer,
L.I.Wu,
M.Emerman,
and
M.H.Malim
(2001).
HIV-1 infection requires a functional integrase NLS.
|
| |
Mol Cell, 7,
1025-1035.
|
 |
|
|
|
|
 |
V.Molteni,
J.Greenwald,
D.Rhodes,
Y.Hwang,
W.Kwiatkowski,
F.D.Bushman,
J.S.Siegel,
and
S.Choe
(2001).
Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain.
|
| |
Acta Crystallogr D Biol Crystallogr, 57,
536-544.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|